Genetic markers for SSG resistance in Leishmania donovani and SSG treatment failure in visceral leishmaniasis patients of the Indian subcontinent.

The current standard to assess pentavalent antimonial (SSG) susceptibility of Leishmania is a laborious in vitro assay of which the result has little clinical value because SSG-resistant parasites are also found in SSG-cured patients. Candidate genetic markers for clinically relevant SSG-resistant parasites identified by full genome sequencing were here validated on a larger set of clinical strains. We show that 3 genomic locations suffice to specifically detect the SSG-resistant parasites found only in patients experiencing SSG treatment failure. This finding allows the development of rapid assays to monitor the emergence and spread of clinically relevant SSG-resistant Leishmania parasites.

[1]  M. Berriman,et al.  Genome-wide SNP and microsatellite variation illuminate population-level epidemiology in the Leishmania donovani species complex , 2012, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[2]  M. Quail,et al.  Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. , 2011, Genome research.

[3]  B. Oury,et al.  Leishmania antimony resistance: what we know what we can learn from the field , 2011, Parasitology Research.

[4]  Syamal Roy,et al.  Use of Antimony in the Treatment of Leishmaniasis: Current Status and Future Directions , 2011, Molecular biology international.

[5]  F. Chappuis,et al.  Linking In Vitro and In Vivo Survival of Clinical Leishmania donovani Strains , 2010, PloS one.

[6]  R. Peeling,et al.  Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? , 2007, Nature Reviews Microbiology.

[7]  V. Yardley,et al.  Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome? , 2007, Microbes and infection.

[8]  V. Yardley,et al.  Epidemiological dynamics of antimonial resistance in Leishmania donovani: genotyping reveals a polyclonal population structure among naturally-resistant clinical isolates from Nepal. , 2007, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[9]  L. Rigouts,et al.  Direct Detection of Mycobacterium tuberculosis Complex DNA and Rifampin Resistance in Clinical Specimens from Tuberculosis Patients by Line Probe Assay , 2006, Journal of Clinical Microbiology.

[10]  S. Rijal,et al.  Antigen genes for molecular epidemiology of leishmaniasis: polymorphism of cysteine proteinase B and surface metalloprotease glycoprotein 63 in the Leishmania donovani complex. , 2004, The Journal of infectious diseases.

[11]  F. Chappuis,et al.  Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[12]  V. Yardley,et al.  Drug sensitivity of Leishmania species: some unresolved problems. , 2002, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[13]  S. Sundar,et al.  Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  S. Sundar,et al.  Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. , 1999, The Journal of infectious diseases.

[15]  N. Van Meirvenne,et al.  Antigenic variation in syringe passaged populations of Trypanosoma (Trypanozoon) brucei. 1. Rationalization of the experimental approach. , 1975, Annales de la Societe belge de medecine tropicale.